General information and entertainment, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Consult a registered adviser before acting.
1. Opening Hook
The June call almost didn’t happen. The 2nd June session was cancelled after a medical emergency involving Chairman Atul Modi, and the whole thing shifted to 29th June with CFO Namrata Modi chairing in his place. A dental-materials company that sells calm and hygiene opened its year-end call recovering from a scare of its own.
The numbers arrived steady. Full-year revenue climbed to roughly ₹72 crore, net profit to about ₹21 crore, and the balance sheet still carries zero debt. Then the fourth quarter walked in and sales barely moved — up under 2%.
A firm exporting to more than 90 countries spent the year explaining wars, tariffs and shipping. The profit held. The stock, over twelve months, did the opposite. That gap is the story.
2. At a Glance
- FY26 revenue ~₹72 Cr (up ~14%) – Growth arrived; it just checked its passport at every border first.
- Q4 sales up under 2% – The quarter that management called “more challenging” declined to grow much, in fairness to the label.
- Net profit ~₹21 Cr, OPM 35.6% – Margins stayed thick while the top line thinned. A company that would rather earn well than sell fast.
- Zero debt, current ratio 14.8 – The balance sheet is so clean it squeaks.
- Inventory days 235, up from 208 – Stock that sits for two-thirds of a year, waiting for a war to end.
- Dividend payout 0% – Down from 7% a year earlier. The cash stayed home.
- Stock down 30.7% over one year – The market read the same results and priced a different mood.
3. Management’s Key Commentary
Management leaned on adjectives all afternoon. Here are the verbatim highlights, decoded.
“Financial year 2025-’26 was a year of steady growth, disciplined execution and continued strategic progress.” → (Three virtues, zero verbs. The sentence works whether revenue rose 14% or 4%.)
“We successfully mitigated inflationary pressures while maintaining healthy profitability.” → (Costs went up; margins didn’t. Somebody in procurement earned their tea.)
“Looking ahead, we remain optimistic about the opportunities before us while continuing to remain prudent in light of global uncertainty.” → (“Optimistic” and “prudent” in one breath — the corporate equivalent of a foot on both pedals.)
“[The UAE subsidiary] we have opened in the month of February and only. So, in March, this crisis happened.” — Namrata Modi → (One month of operations before the region interrupted. The launch and the war shared a calendar.)
“We don’t have the exact number yet. I will pass on the exact number to you.” — Dr. Sai Kalyan, on R&D spend → (Asked what share of revenue funds research, the Director of Research fielded it with a promissory note.)
“Everyone is at the same level. Probably we are slightly ahead than the other MNCs.” — Dr. Sai Kalyan, on digital dentistry → (The pitch versus Ivoclar and Dentsply rests on a “probably” and a “slightly.” Confidence, rationed.)
“There’s a small drop of just 2%. So, we will compensate this loss this year.” — Dr. Sai Kalyan, on Oradox oral care → (The one line that went backwards got the softest word in the deck: “just.”)
4. Numbers Decoded
Prevest runs a rare model for a small cap: it prints high margins and carries no borrowings. The figures below are the reported standalone financials, full year leading with the quarter alongside.
| Metric | FY26 | Q4 FY26 |
|---|---|---|
| Sales | ₹71.7 Cr | ₹18.9 Cr |
| Operating Profit | ₹26 Cr | ₹7.09 Cr |
| OPM | 35.6% | 37.51% |
| Net Profit | ₹21.4 Cr | ₹6.06 Cr |
| EPS (reported) | ₹17.85 | ₹5.05 |
The quarter’s OPM of 37.51% is the highest of the eight quarters on record — margins widened even as the top line stalled. Sales in Q4 rose 1.94% year on year, the softest print in this table by a distance. Net profit still grew about 15% in the quarter, so the profit line kept walking while revenue stopped for directions. The market pays roughly 21x earnings against an industry figure of 37x. EV/EBITDA sits at 12.5, and debt sits at zero.
5. Analyst Questions
Rahul Sharma (individual investor): Growth has slowed from the last three or four years — why? Management’s reply: early-stage companies always show big numbers, and 17.5% export growth is “very, very satisfactory” given the geopolitics. → The question asked why the pace fell; the answer explained why the pace was fine.
Rahul Sharma again: What percentage of revenue goes to R&D? Passed to the R&D head, who didn’t have the figure. → A number that a research-led pitch might want on a slide, filed under “will revert.”
Yash Modi (Ashika Group): Purpose of the Dubai and US subsidiaries, and current capacity utilisation? Answered: US business up ~38%, traditional plant at 67–68%. → A straight question that got a straight-ish answer, which stood out.
Yash Modi: Steps taken to grow domestic sales? The CMO began answering — and the line dropped mid-sentence, twice, before he finished. → The one question on domestic strategy was the one the phone couldn’t handle.
6. Guidance & Outlook
Everything here is management’s own framing, quoted and attributed to them.
On capacity, the Financial Advisor said the traditional line runs at 67–68%, and at full installed capacity the company’s turnover “would be around, say, INR125 crores” — implying meaningful headroom before new bricks are needed. The newer lines (digital, resins, disinfectants, oral care) run at just 18–20%, which management framed as room to grow rather than a gap to explain.
On digital dentistry, Dr. Sai Kalyan said the company expects at least 40% of dental-office procedures to run a digital workflow within five years, and aims for a fully indigenous 3D printer by 2028. Management also flagged OEM arrangements with three or four large companies today, with “another couple” expected within two years.
On the setbacks, management said the Oradox drop would be compensated “this year,” and that Dubai online sales would “most probably” start the next month. The outlook is a list of “next month,” “this year,” “by 2028.” The calendar is doing a lot of the guiding.
7. Risks & Red Flags
- Working capital is stretching. Inventory days rose to 235 from 208, and the cash conversion cycle sits at 227 days — a firm that ties up cash for most of a year.
- Working capital days jumped to 134 from 82. The trend is one direction, and it isn’t down.
- Q4 revenue growth of under 2% shows how quickly the top line can stall when export shipping and ordering patterns wobble.
- Export dependence. Management repeatedly cited tariffs, war and shipping disruption; a business spanning 90-plus countries carries 90-plus places for something to go wrong.
- Oradox fell 2% as US (MoCRA registration) and Dubai (post-war) shipments were held back, per management.
- Dividend payout dropped to 0% in FY26 from 7% the prior year.
8. Badi Badi Baatein Vadapao Khate, Will Management Walk the Talk?
The track record is where the swagger meets the spreadsheet. On the growth question, management said early-stage numbers are naturally large — and the data agrees the pace has eased: five-year sales growth of about 20% has cooled to roughly 13% over three years and about 14% on a trailing basis.
The sharper thread is ROCE. It ran at 47% in FY21, then stepped down almost every year since — 40%, 32%, 27%, and 25% in each of the last two years. Still enviable for a small cap; just visibly narrower than the company it used to be.
The digital story carries real receipts this year — 3D printer sales up 162% and 3D resins up 40.5%, per management — but both sit on small bases, and the “slightly ahead of the MNCs” claim rests on management’s own word. Meanwhile the UAE subsidiary, opened in February, hadn’t commenced commercial operations by the June call. The promise cadence — “next month,” “this year,” “by 2028” — is the thing to hold management to.
9. EduInvesting Take
The strengths are plain and unusual together: zero debt, OPM near 36%, ROCE at 25%, promoter holding steady at 73.6%, and a genuinely differentiated push into digital dentistry with early volume growth. A current ratio of 14.8 means liquidity is not the problem.
The weaknesses are equally plain: a working-capital cycle that keeps lengthening, a fourth quarter where sales grew under 2%, an oral-care line that shrank, a UAE subsidiary still waiting to trade, and an R&D-led narrative whose R&D head couldn’t quote the R&D spend. The dividend went to zero.
Both sides are real; neither cancels the other. What to watch next quarter, all company metrics: whether inventory and working-capital days stop climbing; whether Dubai online sales actually begin as management said; whether Oradox recovers the 2% it lost; whether the 3D printer and resin growth rates hold as bases enlarge; and whether Q4’s revenue softness was a war-shipping blip or a new run-rate. The results answer that, not the narration.
10. Conclusion
Prevest DenPro spent FY26 proving it can protect profit through almost anything — tariffs, a Middle East conflict, a chairman’s health scare, even a dropped phone line during the one question about domestic strategy. The margins held; the debt stayed at zero. What it hasn’t yet proven is that it can grow the top line as fast as it grows its list of “coming soon” ventures. A company with 35%-plus margins and inventory sitting for 235 days isn’t short of quality — it’s short of a reason for the cash to move.
Written by EduInvesting Team
Sources: Prevest DenPro Limited FY26 earnings call transcript (29 June 2026); BSE regulatory filing (Regulation 30/46); company financial data sheet.